Physician profile
John E Burney
NPI 1053315820
$4,970.91
in general payments reported to CMS, 2019-2025
36 companies · $844 in 2025
The $844 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,158 · 2020: $350 · 2021: $143 · 2022: $553 · 2023: $883 · 2024: $1,040 · 2025: $844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,766.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,146.67 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $603.22 | 2019-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $406.75 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $335.03 | 2019-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $325.32 | 2022-2025 | Epclusa, Livdelzi |
| Ironwood Pharmaceuticals, INC | $187.02 | 2019-2023 | Linzess |
| Braintree Laboratories, INC. | $186.00 | 2019-2023 | Suflave |
| Genzyme Corporation | $148.37 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $145.39 | 2023-2024 | Dupixent |
| Ferring Pharmaceuticals INC. | $138.66 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $138.35 | 2019-2024 | Ocaliva |
| Boston Scientific Corporation | $132.96 | 2020-2025 | Sensation Short Throw, Resolution 360 Ultra Clip |
| Madrigal Pharmaceuticals | $114.35 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $96.78 | 2019-2025 | |
| Organon LLC | $81.30 | 2023-2025 | Hadlima, Renflexis |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $70.50 | 2019-2024 | Dificid |
| Daiichi Sankyo INC. | $67.66 | 2019-2023 | Injectafer |
| Ipsen Biopharmaceuticals, INC | $67.65 | 2024-2025 | Iqirvo |
| Celgene Corporation | $62.27 | 2023-2024 | Zeposia |
| Amgen INC. | $51.69 | 2021-2022 | |
| Qol Medical, LLC | $47.33 | 2023-2024 | Sucraid, Sucraid |
| Fresenius Kabi USA, LLC | $46.66 | 2023-2024 | Idacio |
| Romark Laboratories, Lc | $43.14 | 2019 | |
| Pentax of America, INC. | $43.10 | 2021-2022 | |
| Allergan, INC. | $37.47 | 2019-2020 | |
| Lilly USA, LLC | $36.40 | 2023-2025 | Omvoh |
| Ardelyx, INC. | $35.96 | 2023 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $34.69 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $31.76 | 2025 | Zenpep, Vowst |
| Axonics, INC. | $25.73 | 2024 | Axonics |
| Novo Nordisk INC | $17.63 | 2025 | Wegovy |
| Esperion Therapeutics, INC. | $14.86 | 2020 | |
| Mauna Kea Technologies, INC. | $14.02 | 2025 | |
| Shionogi INC | $13.34 | 2019 | |
| Alfasigma USA, INC. | $11.46 | 2020 | |
| Alexion Pharmaceuticals, INC. | $11.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Burney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.